Ropivacaine 0.25% Injectable Solution — Competitive Intelligence Brief

Ropivacaine 0.25% Injectable Solution (Ropivacaine 0.25% Injectable Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesiology.

phase 3 Local anesthetic Voltage-gated sodium channels Anesthesiology Small molecule

Target snapshot

Ropivacaine 0.25% Injectable Solution (Ropivacaine 0.25% Injectable Solution) — Rothman Institute Orthopaedics. Ropivacaine is a local anesthetic that works by blocking nerve impulses, preventing pain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ropivacaine 0.25% Injectable Solution TARGET	Ropivacaine 0.25% Injectable Solution	Rothman Institute Orthopaedics	phase 3	Local anesthetic	Voltage-gated sodium channels
ropivacaine and ketorolac	ropivacaine and ketorolac	University of Aarhus	marketed	Local anesthetic + NSAID combination	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac)
Control (bupivacaine)	Control (bupivacaine)	Kasr El Aini Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
0.33% ropivacaine 250ml	0.33% ropivacaine 250ml	Guangzhou General Hospital of Guangzhou Military Command	marketed	Local anesthetic	Voltage-gated sodium channels
Remifentanil+Lidocaine	Remifentanil+Lidocaine	The First Affiliated Hospital of Zhengzhou University	marketed	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
carbamazepine ER (Equetro)	carbamazepine ER (Equetro)	Massachusetts General Hospital	marketed	Anticonvulsant; mood stabilizer	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class